Practical implications of gene-expressionbased assays for breast oncologists, Nat Rev Clin Oncol, vol.9, pp.48-57, 2011. ,
Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive Breast Cancer, Am Soc Clin Oncol Clin Prac Guideline, vol.34, pp.1134-50, 2016. ,
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, vol.67, pp.290-303, 2017. ,
New prognostic factors for breast cancer recurrence, Semin Oncol, vol.28, pp.53-67, 2001. ,
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype, Ann Oncol, vol.26, pp.1685-91, 2015. ,
Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, vol.27, pp.1160-1167, 2009. ,
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrineresponsive early breast cancer, Clin Cancer Res, vol.20, pp.1298-305, 2014. ,
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay, BMC Med Genomics, vol.8, p.54, 2015. ,
Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study, Curr Med Res Opin, vol.32, pp.835-839, 2016. ,
Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod Pathol, vol.11, pp.155-68, 1998. ,
Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update, J Clin Oncol, vol.36, pp.2105-2127, 2018. ,
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.19, p.90313, 1991. ,
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group, J Natl Cancer Inst, vol.103, pp.1656-64, 2011. ,
Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, vol.24, pp.206-229, 2013. ,
Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, pp.8-30, 2015. ,
Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer, N Engl J Med, vol.379, pp.111-121, 2018. ,
70-Gene Signature as an Aid to treatment decisions in early-stage breast cancer, N Engl J Med, vol.375, pp.717-746, 2016. ,
Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline focused update, J Clin Oncol, vol.35, pp.2838-2885, 2017. ,
Clinical utility of gene-expression signatures in early stage breast cancer, Nat Rev Clin Oncol, vol.14, pp.595-610, 2017. ,
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy, J Clin Oncol, vol.31, pp.2783-90, 2013. ,
Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others, J Natl Cancer Inst, vol.108, p.50, 2016. ,
A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse, Clin Cancer Res, vol.23, pp.3035-3079, 2017. ,
Luminal a breast cancer and molecular assays: a review, Oncologist, vol.23, pp.556-65, 2018. ,
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer, J Natl Cancer Inst, vol.101, pp.736-50, 2009. ,
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials, Ann Oncol, vol.18, pp.1477-1483, 2007. ,
Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes, J Clin Oncol, vol.24, pp.1260-1263, 2012. ,
Tailoring therapies -improving the management of early breast cancer: St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, vol.26, pp.1533-1579, 2015. ,
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, vol.22, pp.1736-1783, 2011. ,
De-escalating and escalating treatments for early-stage breast cancer: the St, Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer, vol.28, pp.1700-1712, 2017. ,
The molecular diversity of Luminal A breast tumors, Breast Cancer Res Treat, vol.141, pp.409-429, 2013. ,
Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors, Oncotarget, vol.8, pp.21733-21773, 2017. ,
An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG), Acta Oncol, vol.57, pp.83-92, 2018. ,
Ki67 assessment in breast cancer: an update, Pathology, vol.49, pp.166-71, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01675161
An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer, Mod Pathol, vol.32, pp.59-69, 2018. ,
Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years, Hum Pathol, vol.39, pp.584-90, 2008. ,